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February 2011550 Abstractspatients would need to be treated to prevent one episode of PE or DVT.
Serious adverse events were 0.7% with fondaparinux, and 1.1% with placebo,
with major bleeding occurring in one patient in each group.
Comment: The number needed to treat, based on relative risk reduc-
tion, demonstrated in the trial to prevent one episode of PE with fondapa-
rinux in patients with SVT is 300. This is similar to the number needed to
treat with low-molecular-weight heparin compared with placebo or no
treatment in trials of VTE prophylaxis in acutely ill medical patients (345,
Dentali F, Ann Intern Med 2007;146:278-88). Treatment with fondapa-
rinux also reduced the risk of symptomatic recurrence of SVT and extension
to the saphenofemoral junction. Because both of these events may result in
escalation of therapy, these end points are clinically relevant. Overall, the
data indicate that with pharmacologic therapy it is possible to improve
the natural history of SVT. Cost effectiveness and effects on quality of life
of the 45-day treatment regimen of fondaparinux for SVT will need to
be evaluated both with respect to the cost of fondaparinux and the cost of
diagnostic testing to determine eligibility for treatment.
Long-Term Outcome of Symptomatic Severe Ostial Vertebral Artery
Stenosis (OVAS)
Karameshev A, Schroth G, Mordasini P, et al. Neuroradiology 2010;52:
371-9.
Conclusion: Vertebral artery stenting can be performed with minimal
periprocedural complications. Potential benefits are most likely in those with
bilateral vertebral artery stenosis.
Summary: About 25% of all strokes are posterior circulation strokes
(Bogousslavsky J, Stroke 1988;19:1083-92). Of posterior circulation
strokes, 20% to 25% are associated with a severe ostial stenosis or occlusion
of the vertebral artery (Wityk RJ et al, Arch Neurol 1998;55:470-478).
c
rndovascular management of vertebra artery stenosis is infrequently re-
orted. The only randomized trial, The Carotid and Vertebral Artery
ransluminal Angioplasty Study (CAVATAS, Coward LJ, Stroke 2007;38:
526-1530), enrolled only 16 patients with vertebral artery stenosis. An
dditional trial, the Vertebral Artery Stenting (VAS) trial, may be underway
Trials 2008;9:65). Results are unlikely to be available for many years.
In this study by Karameshev et al, 39 consecutive patients with a
ecently symptomatic (48 hours) severe (70%) ostial vertebral artery
tenosis were evaluated in a single-institution study. Treatment of patients
as medical (n 29) or by vertebral artery stenting (n 10) and was left to
he discretion of the treating physician. Mean follow-up was 2.8 years. Data
ere analyzed using the Kaplan-Meier method for risk of recurrent stroke,
ransient ischemic attack (TIA), or death. Stented patients were younger and
ore likely to have bilateral vertebral artery disease (P  .04 and P  .02).
ertebral artery stenting was successful in all 10 patients. One patient had a
eriprocedural transient ischemic attack. There was restenosis of one verte-
ral artery stent at 9 months. At 4 years of follow-up there was no statistical
ifference in the risk of a combined end point of TIA and stroke in the
osterior circulation in stented (10%) compared with medically treated
atients (45%; relative risk, 0.24; 95% confidence interval, 0.031-1.85; P 
095). Patients with bilateral vertebral disease had 0% recurrence of symp-
oms after stenting at 4 years compared with 91% for medical treatment
relative risk, 0.10; 95% confidence interval, 0.022-0.49; P  .004).
Comment:The study was not randomized and the patients were highly
elected for treatment. Clearly, the study does not provide sufficient data to
ustify a widespread approach to endovascular management of vertebral
rtery stenosis. Medical management remains the mainstay for patients with
ymptomatic vertebral artery stenosis with intervention by open or endovas-
ular techniques reserved for highly selected patients using what amounts to
eally no more than “best guess” criteria.
